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Abstract
Objectives
Dietary phenylalanine restriction is the main treatment of 
phenylketonuria (PKU, OMIM 261600). There are a number of studies 
which have demonstrated growth retardation in these patients, and 
some are in contrast. This study was performed to assess the growth 
parameters of treated PKU patients.
Materials & Methods
This cross-sectional study was performed between 2015 and 2017 to 
compare growth indexes in PKU patients in our clinics with normal 
age and sex matched controls. Weight, height, head circumference 
(HC), weight for height and BMI (weight/height2) were measured and 
converted into Z-scores. We assessed differences between patients and 
controls’ anthropometric indices in all patients and separately in patients 
who were diagnosed by newborn screening program and patients 
who were diagnosed after presentation of clinical manifestations in 
comparison with age and sex-matched controls. Also, this difference 
was assessed separately in patients aged two years and less. Correlations 
between pretreatment plasma phenylalanine concentrations mean 
plasma phenylalanine concentrations and anthropometric parameters 
were analyzed in the patients.
Results
 Overall, 209 under-treatment PKU patients (103 males, 106 females; 
mean age 9.29 ± 8.7 years) and 216 controls (109 males and 107 
females; mean age 8.98 ± 8.62 years) matched in terms of age, sex 
and birth weight were enrolled in this study. In general, 130 patients 
were diagnosed by newborn screening and 79 were diagnosed when 
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they became symptomatic before the screening program. A significant 
difference (p=0.000) was found only in HC z-score and weight for 
height z-score in comparison with the control group, when we assessed 
all patients. We did not find any significant differences in any of the 
anthropometric indices between cases and controls who were aged 2 
years old and less. Head circumference SDS and weight for height 
SDS were significantly different when patients and controls who were 
more than 2 years old were compared. Mean HC was significantly 
lower in patients, while BMI SDS, weight SDS, and weight for height 
SDS were significantly higher in PKU patients in comparison with 
the control group when patients who were diagnosed in newborn 
screening were assessed. Head circumference SDS, BMI, height SDS 
and difference between patients’ height SDS and mid parental height 
SDS had significantly lower mean scores in comparison with those of 
the control group, while mean weight SDS was significantly higher 
compared to controls when patients who were diagnosed after clinical 
presentation were assessed.
 Mean phenylalanine was not correlated with anthropometric indices, 
while there was a correlation between pretreatment phenylalanine and 
HC. 
Conclusion
Disparities in anthropometric indexes changes observed in different 
studies may be due to diverse diet protocols, availability of various 
specific products and micronutrient substitutes.
Keywords: Phenylketonuria; Growth Parameters; phenylalanine 
Level; Dietary restriction
Introduction
Phenylketonuria (PKU) stems from phenylalanine 
hydroxylase enzyme deficiency where the essential 
amino acid phenylalanine (Phe) is not converted 
into tyrosine. Accumulation of phenylalanine and 
its metabolites damages developing neural system 
in patients. 
Despite new approaches for the treatment of PKU, 
natural protein and phenylalanine-restricted diet 
and administration of Phe free protein substitutes 
for PKU patients are the main treatments for 
achieving normal plasma phenylalanine and 
preventing complications of high phenylalanine 
levels, such as mental retardation, although some 
degree of neuropsychological dysfunction may 
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remain (1, 2). Also, adhering to this kind of diet 
results in a number of complications such as 
micronutrients, minerals, vitamins and essential 
fatty acids deficiency; thus, each patient’s dietary 
habits should be considered to acquire milestones 
and have a normal growth (3-5).
Several studies have been designed for the 
assessment of growth in PKU patients and finding 
the effects of Phe-restricted diet on physical growth 
of PKU patients under treatment, but inconsistent 
findings have been achieved (6-10). 
Herein, we measured growth parameters, weight 
for height and BMI in patients who were under 
Phe-restricted diet. We also considered familial 
and constitutional short stature in these patients. 
Furthermore, we examined the correlation between 
patients’ physical growth and their pretreatment 
and mean plasma phenylalanine concentrations, 
which are signs of disease severity and dietary 
adherence, respectively.
Material & Methods
This cross-sectional study was performed from 
2015 to 2017 in PKU clinics in Mofid Children’s 
Hospital, where the patients were followed up (a 
referral hospital). We considered a patient to have 
PKU if plasma phenylalanine concentrations were 
> 6 mg/dl in untreated newborn infants (child). The 
study was approved by the Ethics Committee of 
Shahid Beheshti University of Medical Sciences.
Z-score of head circumference (HC), body mass 
index (BMI: weight/height2), weigh, and height 
were compared between PKU patients matched in 
terms of age, sex and birth weight. We selected age 
and sex-matched controls from normal children 
who visited our endocrine clinics for following their 
growth and they are completely normal without any 
underlying or chronic diseases. For participants 
with age? more than 20 years, we selected controls 
from our medical staff and medical students.
We performed height measurement for patients 
who were more than 2 years old with wall-
mounted stadiometer, asking the patient to stand 
erect, remove bulky clothing, hair ornaments and 
shoes, put heels together and arms at sides, look 
straight ahead so that the line of sight was parallel 
with the floor. Recumbent length measurements 
for children less than 2 years old were done by 
an infantometer. Weight measurements were 
performed by Seca mechanical medical and 
baby scales. Occipitofrontal circumference, 
(circumference of the head around the occiput of 
the skull to the most anterior portion of the frontal 
bone), were measured as HC, by a flexible tape 
measure.
All the measurements were performed by a single 
clinical physician and same measure instruments.
Weight, height, HC (< 3 years), weight for height 
(<2 y/o) and BMI (>2 y/o) were tracked into NCHS 
centiles. Head circumference for the patients 
above 3 y/o were tracked to charts, modified from 
Nelhaus G, J pediatr 1968;48:106 (11).
As the measurements were not performed at the 
same ages in patients, height, weight and HC 
were transformed into Z-scores by subtracting 
the patient’s measurements from expected mean 
measurement for those of age and sex, and dividing 
it by its standard deviation. Z-scores between -2 
and +2 considered as normal range. 
Furthermore, correlation between pretreatment 
plasma Phe concentrations, mean plasma 
Phe concentrations during treatment, and 
anthropometric parameters were analyzed in the 
patients.
Initial dietary protocols depended on the maximum 
pretreatment Phe plasma levels (70 mg/kg/day 
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phenylalanine was recommended for the initial 
plasma Phe <10 mg/dl ,55 mg/kg/day for plasma 
Phe 10-20, 45 mg/kg/day for 20-30 mg/dl, 35 mg/
kg/day for 30-40 mg/dl and 25 mg/kg/day for 
initial Phe >40 mg/dl) (12). Dietary Phe intake 
was adjusted to achieve blood Phe levels between 
2-6 mg/dl in patients <12 years old and between 
2-10 mg/dl in patients >12 years old (13). This 
level of control was considered as appropriate, 
and blood Phe less than 2 mg/dl was considered 
as overtreatment (13). Plasma Phe concentrations 
were measured by the fluorometric method, which 
is a quantitative and precise method (14). The 
mean of plasma Phe concentration for each patient 
was calculated, considering the maximum Phe 
measurements throughout a year.
Informed consent was obtained orally from the 
parents and patients who were mature and not 
mentally retarded.
We also compared anthropometric measures with 
those of the control group separately for patients 
who were diagnosed in screening and patients who 
were diagnosed after presentation of clinical signs 
and symptoms, we also compared anthropometric 
indexes in patients who were equal or less than 2 
years old and patients who were more than 2 years 
old with the age-matched control group separately.
Statistical Method
This cross-sectional study was performed from 
2015 to 2017 in PKU clinic affiliated to Mofid 
Children’s Hospital.
Data were analyzed in SPSS version 22. 
Distribution of values assessed by One Sample 
Kolmogorov-Smirnov test and distribution of all 
values were abnormal, except for midparental 
height z-score. Mann-Whitney test was used for 
analyzing the data. P-value (predictive value) 
<0.05 was considered statistically significant. 
We used correlation analysis to assess the effect 
of pretreatment and intratreatment phenylalanine 
levels on anthropometric indexes.
Results
Overall, 209 PKU patients (103 males, 106 
females; mean age 9.29 ± 8.7 years, range 1 month 
to 44 years) were enrolled in our study. In general, 
130 patients were diagnosed by newborn screening 
and 79 patients were diagnosed when they became 
symptomatic before the screening program. 
Our control group consisted of 216 age and sex-
matched controls (mean age: 8.98 ± 8.62 years, 
range 1 month to 44 years, median years) selected 
from normal children and adults. Phenylketonuria 
patients consisted of patients who were diagnosed 
before screening based on clinical manifestations 
(79 patients, mean age: 18.3 ± 7.74 years, age 
range: 4.16 to 44 years) and patients who were 
diagnosed by the newborn screening program 
before presenting clinical manifestations (128 
patients, mean age: 3.75± 2.21 years, age range: 
0.12 to15 years). 
Anthropometric measures of patients were 
compared with those of the control group in this 
study.
Mean, median, and standard deviation of 
weight z-score, height z-score, HC z-score, and 
BMI z-score of PKU patients and controls are 
summarized in Table 1.
Phenylketonuria patients versus control group
Weight SDS, height SDS, BMI SDS, weight for 
height SDS and HC SDS of all the PKU patients 
were compared with the control group.
There were significant differences between the 
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PKU patients and the control group in HC SDS 
(z-score) and weight for height SDS (P=0.000 for 
both variables). Mean HC in the PKU patients was 
- 0.68± 1.34 cm, whereas this value was 0.081± 
0.94 cm in the control group. Mean weight for 
height z-score in the PKU patients was 1.21± 2.05, 
whereas this value was 0.51± 1.76 in the control 
group (Table1). We did not find any significant 
differences in weight SDS, BMI SDS, and height 
SDS between the cases and controls.  
Difference between patients’ height SDS and mid-
parental height SDS was not significantly different 
in patients (mean ± SD: 1.9±1.14) and the control 
group (mean ± SD: 2±1.05) (P=0.81). 
Phenylketonuria patients 2 years old and lower 
versus age and sex-matched controls 
Weight SDS, height SDS, weight for height SDS, 
and HC SDS were compared between PKU patients 
who were less than 2 years old and age and sex 
matched controls. We did not find any statistically 
significant difference in any of the anthropometric 
indexes between cases and controls. Descriptive 
statistics are summarized in Table 2.
Phenylketonuria patients with more than 2 
years old versus control group
Weight SDS, height SDS, BMI SDS, HC SDS and 
difference between height SDS and mid-parental 
height SDS were compared between cases and the 
age and sex-matched control group.
Head circumference SDS and weight for height 
SDS were significantly different between the two 
groups. P-value was 0.000 for both variables. The 
mean HC z-scores in case and control groups were 
-0.75 and -0.1, respectively. Weight for height SDS 
was also significantly different between patients 
and controls (P=0.000). Mean weight for height 
SDS was -0.89±2.1 and -0.15±1.7 in patients and 
controls, respectively. Thus, PKU patients had a 
higher weight for height SDS in comparison with 
the control group. Other anthropometric indexes 
were not significantly different in patients and 
controls. Descriptive statistics are summarized in 
Table 2.
Phenylketonuria patients who were diagnosed 
in newborn screening versus patients who were 
diagnosed after presenting clinical signs and 
symptoms
We analyzed patients who were diagnosed in 
newborn screening and those diagnosed after 
presenting clinical manifestations before newborn 
screening program separately with regard to 
probable differences in anthropometric indexes.
Body mass index SDS, weight SDS, weight 
for height SDS and HC SDS were significantly 
different in patients who were diagnosed during 
newborn screening in comparison with the age 
and sex-matched control group. Mean HC was 
significantly lower in PKU patients, while BMI 
SDS, weight SDS, and weight for height SDS were 
significantly higher in PKU patients in comparison 
with the control group. Height SDS and difference 
between patients’ height SDS and mid parental 
height SDS were not significantly different. 
P-values are presented in Table 3.
Weight SDS, BMI SDS, height SDS, difference 
between patients’ height SDS and mid parental 
height SDS and HC SDS were significantly 
different in patients who were diagnosed after 
presenting clinical manifestations in comparison 
with the control group. The means of HC SDS, 
BMI, height SDS and difference between patients’ 
height SDS and mid parental height SDS were 
significantly lower in comparison with the control 
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group, while mean weight SDS was significant 
higher compared to that of the controls. Values are 
demonstrated in Table 3. 
Weight SDS, BMI SDS, height SDS, difference 
between patients’ height SDS and mid parental 
height SDS and HC SDS were significantly higher 
in patients who were diagnosed in the screening 
program in comparison with patients who were 
diagnosed after presenting clinical manifestations 
(P=0.001, 0.033, 0.01, 0.000, respectively). 
Descriptive statistics are summarized in Table 3.
Pretreatment and mean plasma phenylalanine 
concentrations
The mean of patient’s pretreatment phenylalanine 
Table 1. Weight, height and head circumference z-scores of the phenylketonuria patients and the control group
Values Age (year) HC1 SDS Ht 2 SDS*
ΔHtsds & 
MPH 3SDS
Wt 4 SDS WFH 5 SDS BMI 6 SDS
Case/
control
Case    
control
Case    
control
Case    control Case    control Case    control
Case   
control
Case    control
Mean 9.29    8.98 -0.68     0.08 -0.44    -0.31 1.94         2.02 0.24      0.24  1.21     0.51 0.815    0.60
median 5.33     5 -0.55     0.14 -0.34    -0.470 -.15         0.2 -0.08      0.12 0.27      0.11 0.493    0.18
SD** 8.7      8.6 1.34      0.94 1.32      1.08 1.14        1.05 1.83       1.88 2.05      1.76 2.09     2.11
Minimum 0.12     0.12 -4.03     -2.66 -5.91     -3.3 -0.21        0.47 -3.08      -3.5 -3.22     -3.22 -5.11     -4.59
Maximum 44      44 2.70      2.37 3.49      2.97 5.58         4.55 9.67      11.29 8.37      7.2      9.23     11.54
P. values 0.000 0.37 0.81 0.9 0.000 0.3
1 HC: head circumference
2 Ht: Height
3 Δ Htsds & MPH: difference between height SDS and mid parental height SDS
4 Wt: weight
5 WFH: weight for height
6 BMI: body mass index
*SDS: standard deviation score: z-score
** SD: standard deviation
(phenylalanine of the time of diagnosis) was 21.24 
± 8.86 mg/dl (range: 7 to 47).
There was a significant negative correlation 
between HC z-score and pretreatment Phe 
concentrations (r= -0.445, P=0.01).
We did not find any correlation between 
pretreatment Phe and other anthropometric 
measures.
There was a significant positive correlation between 
mean phenylalanine and weight SDS (r=0.24, 
P=0.001) and BMI SDS (r=0.22, P=0.006) Mean 
intratreatment phenylalanine was not significantly 
correlated with height SDS, HC SDS, and weight 
for height SDS. 
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Discussion
Phenylalanine-restricted diet is the most important 
treatment in classical PKU until now. Several 
studies have been designed to evaluate the effect of 
diet therapy on PKU patients’ growth. Interestingly, 
different results have been reported. Therefore, we 
designed this case-control study to compare growth 
in PKU patients who were under diet therapy with 
normal age and sex-matched Iranian children. 
In this study, we found that Iranian PKU patients 
were not totally different in weight and height 
parameters, but were retarded in HC, and weight 
for height z-score was higher in PKU patients.
We found no difference between mean weight 
z-scores, height z-score, and BMI z-score in 
PKU patients and controls, but when we analyzed 
patients who were diagnosed during screening and 
before screening separately, we found that mean 
HC was significantly lower in PKU patients, while 
BMI SDS, weight SDS, and weight for height SDS 
were significantly higher in patients diagnosed in 
newborn screening program in comparison with 
the controls. Height SDS and difference between 
patients’ height SDS and mid parental height 
SDS were no significant different in this group 
of patients in comparison with the control group. 
It shows that HC is affected in PKU patients in 
spite of  Phe restriction diet because of inevitable 
variation in Phe level even by dieting. It was more 
prominent in patients who were more than 2 years 
old probably because of more difficulty to force 
children in this age group to have commitment to 
a specific diet. 
Higher mean levels in weight SDS, weight for 
height SDS, and BMI SDS in this group of patients 
probably result in high carbohydrate diet in contest 
for providing appropriate calorie and change in 
patients’ appetite. Surprisingly, height SDS was 
not affected in this group of patients in spite of 
Phe (protein) restricted diet. In patients who were 
diagnosed after presenting clinical manifestations 
before newborn screening program, HC SDS, 
BMI SDS, height SDS and difference between 
patients’ height SDS and mid parental height 
SDS had significant lower means in comparison 
with the control group, while weight SDS was 
significantly higher relative to the controls. It may 
be due to neurologic defects in patients that could 
affect patients’ nutrition and physical activity as 
well as parental cares. Although there is dietary 
phenylalanine restriction (low protein diet) in these 
patients which usually causes height reduction, we 
tried to reach an adequate amount of calorie by 
consuming more special formula or foods (high 
carbohydrate diet) that have less phenylalanine, 
resulting in higher weight SDS. In this group, BMI 
SDS was low because height was affected.
Huemer et al. and Holm et al. found no significant 
difference in weight of PKU patients and the 
normal population (7, 15). This result was also true 
about weight, length, and HC of 35 infants studied 
by Acosta et al. However, plasma phenylalanine 
concentration was not correlated with growth (16). 
On the contrary, McBurnie et al. found that mean 
weight was significantly different (p<0.05) between 
PKU and NCHS groups at most ages for both sexes 
(17). Also, Dobbelare et al. found PKU patients 
were shorter and lighter than the French reference 
population (18). In a recent study, Luis Aldamiz-
Echevarria et al. reported early-stage weight and 
height growth retardation in PKU patients in 
comparison with the Spanish reference population 
(4). Administration of tetrahydrobiopterin did not 
correct growth (4, 19). Egyptian studies reported 
normal weight and height growth in PKU patients 
and reported that many patients became obese or 
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overweight (20, 21). Susceptibility to increased 
fat mass was reported in PKU patients, especially 
in female patients above 11 years old in the 
Netherlands (8), but Rocha et al. did not find any 
statistically significant difference in fat mass and 
incidence of overweight and obesity and metabolic 
syndrome between patients and controls in another 
study (22). 
Dobbelaer et al. reported that PKU patients were 
moderately but significantly shorter (H/A z-score 
varied from -2.12 to 1.61; mean: -0.49) and lighter 
(W/A z-score varied from -2.58 to 1.49; mean: 
-0.71) than the French reference population. Body 
composition in patients was not different from that 
of controls matched for age and sex (6). Rocha et 
al. reported normal growth in 89 PKU patients in 
comparison with controls (7, 9).
Inconsistent results in these studies may be due 
to different techniques of diet therapy in aspects 
of restriction of Phe and protein and usage of 
carbohydrates and fat and calculation of calories. 
Also, rigidity in cradling phenylalanine in advised 
levels and patients’ adherence to therapy may 
be effective in different growth patterns in PKU 
patients. 
We found no significant difference between height 
z-scores of patients and controls less than 2 years 
old, and the cause may be achieving sufficient 
calories and supplements by patients. Also, dietary 
adherence is much easier in patients less than 2 
years old. There was no significant difference in 
height z-score between patients above 2 years 
old and age and sex-matched controls. It shows 
that chronic low protein intake and micronutrient 
deficiency could not affect linear growth in Iranian 
PKU patients. 
Hoeksma showed that there was no relationship 
between energy and protein intake and height 
growth (10). Furthermore, lower height standard 
deviation score may be due to growth hormone 
resistance that is found in almost all chronic 
diseases. However, IGF1, IGFBP3, and thyroid 
hormone levels were within the normal range 
and no relationship was found between plasma 
Phe concentrations, protein or caloric intake and 
the presence of growth retardation in a study by 
Dobbelaere et al. (18). Comparison of height with 
family data by Holm et al. showed that children 
with PKU grew as expected for their genetic 
endowment as we showed in our study in patients 
who were diagnosed in newborn screening (23). 
In a longitudinal study, the mean height SDS 
(z-score) was not significantly different at baseline, 
but it decreased during the second year of life 
and weight for height SDS was in normal range 
in these patients (24). Another study revealed no 
significant difference in height z-score in patients 
less than 19 years old, while height z-score was 
significantly lower in patients above 19 years old 
(9). Aldamiz-Echevarria et al. reported different 
growth manners in different ages in PKU patients. 
There was a positive correlation between height 
growth and height standard deviation score in PKU 
patients in their study (4).
In our study, there was a significant decrease 
in patients’ HC than in controls’, however, by 
comparing patients and controls in the two 
groups, the difference was significant in patients 
above 2 years old. McBurnie et al. found that HC 
in PKU children tended to be lower than NCHS 
standards; however, the maximum difference at 
any age was less than 0.5 cm (17). Verkerk et al. 
found PKU patients had smaller HCs than the 
normal population, and more growth retardation is 
observed in their first three years of life (25).
Head circumference was not smaller in patients 
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less than 2 years old, this might result from 
tighter control and screening in lower ages. The 
negative significant correlation between HC and 
pretreatment plasma Phe was in contrast with 
findings of other studies (17). Hoeksma et al. found 
a positive correlation between natural protein 
intake and HC growth in a study of 174 0 to 3-year-
old patients (26). While finding no correlation 
between growth parameters and mean plasma Phe 
levels (a sign of dietary adherence) could reveal 
that disease severity (pretreatment Phe levels) is a 
more effective factor in HC growth.
There was no difference between weight for height 
in PKU patients and controls (less than 2 y/o), and 
this means that patients are totally in the normal 
range or weight and height were appropriately 
decreased (26). According to our study, patients’ 
weight SDS, BMI SDS, and weight for height SDS 
were higher in comparison with the control group 
probably resulting in high carbohydrate levels. 
Even it was reported by Verkerk et al. that there 
were fewer children lower and higher than 10th 
and 90th weight for height percentile than expected 
(25).
However, no statistically significant difference 
between PKU patients and controls was reported 
by Huemer (7). Dobbelaere et al. also found body 
composition was not different from that of controls 
matched for age and sex (18). 
Another interesting result in our study was absence 
of correlation between mean phenylalanine level 
during treatment and growth indexes; however, 
pretreatment phenylalanine level had a negative 
correlation HC SDS in patients.
In Conclusion, The most important anthropometric 
index that was affected in PKU patients was HC, 
especially in patients with more than 2 years of 
age in spite of the fact that patients were under 
Phe restriction diet. Significantly higher weight 
z-score, BMI z-score, and weight for height 
z-score were seen in patients who were under 
early onset nutritional treatment probably because 
of low protein and high carbohydrate diet. Height 
z-score and BMI z-score were significantly lower 
in patients diagnosed after clinical presentation 
probably because of the existing sequels affecting 
nutrition and activity of patients, while weight 
SDS was significantly higher. Differences in 
anthropometric index changes that observed in 
different studies may be due to disparate diet 
protocols, availability of various specific products 
and micronutrient substitution.
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